116209-30-4

Upstream product

• 501378-89-8 4-bromo-2-dimethylthiocarbamoyloxy-benzoic acid methyl ester 
• 1666-28-0 4-bromosalicylic acid 
• 22717-56-2 4-bromo-2-Hydroxybenzoic Acid Methylester 
• 65-49-6 4-Aminosalicylic acid 
• 135484-83-2 2-amino-4-bromo-benzoic acid methyl ester 
• 501378-90-1 4-bromo-2-dimethylcarbamoylsulfanyl-benzoic acid methyl ester 
• 20776-50-5 2-amino-4-bromobenzoic acid 

Downstream Products

• 881900-17-0 methyl 4-bromo-2-mercaptobenzoate 
• 1336982-65-0 2-(3,4-dichlorobenzylthio)-4-(4-hydroxybut-1-ynyl)benzoic acid 
• 1336982-67-2 4-((3-aminophenyl)ethynyl)-2-(3,4-dichlorobenzylthio)benzoic acid 
• 1336982-72-9 4-((3-chlorophenyl)ethynyl)-2-(3,4-dichlorobenzylthio)benzoic acid 
• 1336982-63-8 4-bromo-2-(3,4-dichlorobenzylthio)benzoic acid 
• 918328-15-1 [4-bromo-2-(methylsulfanyl)phenyl]methanol 
• 881899-92-9 3-amino-6-phenyl[1]benzothieno[3,2-b]furan-2-carboxamide 
• 881900-21-6 2-[(2-cyano-6-phenyl-1-benzothien-3-yl)oxy]acetamide 
• 881900-20-5 3-hydroxy-6-phenyl-1-benzothiophene-2-carbonitrile 

Relevant academic research and scientific papers

Benzimidazole or azabenzimidazole -6 - carboxylic acid compound and application thereof

The invention discloses benzimidazole or azabenzimidazole -6 - carboxylic acid compound and application thereof, wherein the benzimidazole or azabenzimidazole -6 - carboxylic acid compound has the structure shown in the formula (I). The benzimidazole or a

BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS

The present invention provides compounds and pharmaceutical compositions including the compounds for the treatment of a skin disease associated with proteolytic activity of one or more KLK proteases, wherein the compounds are according to formula (I): whe

Synthesis and structure activity relationship studies of benzothieno[3,2-b]furan derivatives as a novel class of IKKβ inhibitors

As a novel class of IKKβ inhibitors, a series of tricyclic furan derivatives was designed and synthesized based on the structure of known thiophene IKKβ inhibitors. Among the various fused furan derivatives synthesized, a benzothieno[3,2-b]furan derivative 13a displayed potent inhibitory activity towards IKKβ in enzymatic and cellular assays. The potent inhibitory activity originates from an intramolecular non-bonded S...O interaction which was confirmed by the X-ray structure of JNK3 with 16k. The introduction of further substituents on the core structure led to the discovery of the 6-alkoxy derivatives, which possessed a comparable IKKβ inhibitory activity to 13a and an improved metabolic stability. Among these, appropriately lipophilic compounds 16a, h, i, and 13g (logD>2) were found to possess good oral bioavailability.

1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF

This invention provides a compound represented by the formula (I) :wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents;R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents;n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.